JRSH
Jerash Holdings (US), Inc.
JRSH has the edge over LCID overall, supported by lower modeled downside and stronger modeled upside.
LCID
Lucid Group, Inc.
LCID's outlook is improving, though it still trails on the overall score.
JRSH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
JRSH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
JRSH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.4x | $4.11 | -44% |
| Fair | 14x | $6.75 | -8.1% |
| Current | 15x | $7.35 | — |
| Forward | 15x | $7.35 | — |
| Expensive | 26x | $12.70 | +73% |
Historical ranges are pointers, not guarantees.
JRSH's PE is in its fair range at 15.0x. On analysts' estimates for next year's earnings, today's price would be 15.2x.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
JRSH Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for JRSH, with profitability improving.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
JRSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.49 | -1% |
| Q3 2026 | $0.49 | +717% |
| Q2 2026 | $0.37 | +429% |
| Q1 2026 | $0.27 | +$0.34 |
| Q4 2025 | $0.15 | +$0.46 |
| Q3 2025 | $0.06 | +$0.35 |
| Q2 2025 | $0.07 | +$0.38 |
| Q1 2025 | -$0.07 | +$0.09 |
| Q4 2024 | -$0.31 | -$0.24 |
JRSH has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
JRSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.3M | +20% |
| Q2 2026 | $50.2M | +27% |
| Q1 2026 | $42.9M | +47% |
| Q4 2025 | $41.8M | +18% |
| Q3 2025 | $42M | +4.3% |
| Q2 2025 | $39.6M | -3.2% |
| Q1 2025 | $29.3M | +36% |
| Q4 2024 | $35.4M | +29% |
JRSH's revenue has grown year over year for five quarters in a row: $50M last quarter, up 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.1% | +3.5 points |
| Q2 2026 | 5.2% | +2.8 points |
| Q1 2026 | 5.5% | +4 points |
| Q4 2025 | 4.7% | +2.7 points |
| Q3 2025 | 2.6% | -0.2 points |
| Q2 2025 | 2.4% | +4.4 points |
| Q1 2025 | 1.5% | +16 points |
| Q4 2024 | 2% | +0.6 points |
JRSH has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over JRSH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
JRSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.4M | -32% |
| Q2 2026 | $2.3M | +$9.3M |
| Q1 2026 | $1.8M | +21% |
| Q4 2025 | -$3.9M | -$750.5K |
| Q3 2025 | $6.4M | +46% |
| Q2 2025 | -$6.9M | -$4.6M |
| Q1 2025 | $1.5M | +$7.3M |
| Q4 2024 | -$3.2M | -$2.7M |
JRSH has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
JRSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -2.6x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -4.6x | Net Cash |
| Q4 2024 | -13.3x | Net Cash |
JRSH has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
JRSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 84.7 | Overbought |
| Stochastic | 74.8 | Neutral |
JRSH's weekly RSI is 85 (overbought) and its Stochastic is 75 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
JRSH PE vs Consumer Cyclical Sector
| Metric | JRSH | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 18x | 17% below |
| PE % | 58 | 47 | 11 pts above |
JRSH is trading at 15x earnings, a 17% discount to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
JRSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.21 | 18% above |
| 20 week MA | $5.50 | 34% above |
| 50 week MA | $4.16 | 77% above |
| 100 week MA | $3.75 | 96% above |
| 200 week MA | $3.60 | 104% above |
JRSH has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
JRSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.02 | $5.52 | -8.3% |
| 2021 | $5.52 | $6.70 | +21% |
| 2022 | $6.70 | $4.03 | -40% |
| 2023 | $4.03 | $3.11 | -23% |
| 2024 | $3.11 | $3.43 | +10% |
| 2025 | $3.43 | $3.03 | -12% |
| 2026 YTD | $3.03 | $7.35 | +143% |
JRSH has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.